White label ELPA - ClinicalTrials.eu

Study on Bepranemab for Patients with Early Alzheimer’s Disease

Not recruiting

2 1 1
Investigated Drugs:
+1
Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

Not recruiting

3 1 1
Investigated Drugs:
- Concizumab
+5
Study Comparing Abemaciclib and Fulvestrant with Placebo and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer After Previous Treatment

Not recruiting

3 1 1
Investigated Diseases:
- Breast neoplasm
Investigated Drugs:
- Abemaciclib
- Fulvestrant
+3
Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Not recruiting

3 1 1 1
Investigated Drugs:
+9
Study of Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Renal Cell Carcinoma

Not recruiting

1 1 1 1
Investigated Drugs:
Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Not recruiting

3 1
Investigated Drugs:
- Risankizumab
+11
Study on Brigatinib for Patients with ALK+ Non-Small Cell Lung Cancer

Not recruiting

2 1 1 1
Investigated Drugs:
- Brigatinib
Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Not recruiting

3 1 1
Investigated Diseases:
- Diffuse large B-cell lymphoma
Investigated Drugs:
+5
Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Not recruiting

3 1
Investigated Drugs:
- Itepekimab
+12
Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

Not recruiting

2 1 1
Investigated Drugs:
- Cetrelimab
- Gemcitabine Hydrochloride
+2

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies